Hayley Virgil

Senior Editor, OncLive®
Hayley Virgil heads OncLive's feature article efforts and specializes in social issues and equality in oncology. Prior to joining the company in early 2020, she worked as an editor in numerous industries, including media, marketing, hospitality, and computer science, and freelanced in subjects such as history, culture, and the natural sciences.

Articles

Targeted Therapies Dominate the Relapsed/Refractory CLL Paradigm

February 27th 2021

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

Remembering Henrietta Lacks: Progressing Clinical Cancer Research and Repairing Trust in the Medical Community

February 27th 2021

Although the research that emerged from the discovery of the HeLa cell line has helped to prevent 4.5 billion global infections and 10.3 million global deaths, the unethical and controversial nature of their discovery has raised issues with regard to privacy and consent in underrepresented patient populations.

Bekaii-Saab Shares Suggested Sequencing Algorithm for Advanced HCC

February 26th 2021

Tanios S. Bekaii-Saab, MD, FACP, shares his approach for treating patients with HCC across several lines of therapy, as well as factors to consider when making sequencing decisions.

CD19-Targeted CAR T-Cell Therapies Induce Durable Remissions in Several Lymphoma Subtypes

February 26th 2021

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

February 25th 2021

Total body irradiation plus etoposide prior to hematopoietic stem cell transplantation resulted in improved overall survival and a lower risk of relapse in pediatric patients with high-risk acute lymphocytic leukemia compared with chemotherapy conditioning.

CAR T-Cell Therapy Explodes on the Scene in Heavily Pretreated Multiple Myeloma

February 24th 2021

Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy.

Biomarker-Guided Therapies, Novel Combos Take Center Stage in Urothelial Carcinoma

February 23rd 2021

Jason Zhu, MD, discusses several approaches under exploration in the treatment of patients with previously treated, locally advanced, or metastatic urothelial carcinoma.

TKI/Immunotherapy Combos Dominate Frontline Metastatic RCC Management

February 22nd 2021

Claud N. Grigg, MD, highlights different frontline combination regimens that are improving outcomes for patients with metastatic renal cell carcinoma.

Cologuard mt-sDNA Test Could Provide a Noninvasive Screening Option for CRC

February 19th 2021

February 19, 2021 - Multitarget stool DNA test Cologuard could present a potential noninvasive screening method for colorectal cancer, as it has demonstrated high specificity among average-risk patients aged 45 to 49 years.

Using MRD to Inform Treatment Decisions in Transplant-Eligible Myeloma

February 18th 2021

Rafael Fonseca, MD, discusses several clinical trials that support the use of quadruplet regimens in myeloma, the utilization of MRD in clinical decision-making, and future directions for research.

Neoadjuvant Tavokinogene Telseplasmid Plus Nivolumab Under Evaluation in Advanced Melanoma

February 17th 2021

The first patient with operable, locally or regionally advanced melanoma has been dosed with the intratumoral DNA plasmid-based interleukin-12 therapy tavokinogene telseplasmid in combination with nivolumab as a neoadjuvant treatment before surgery in the investigator-initiated, phase 2 OMS-104 trial.

Germline Genetic Testing Gap Persists in Ovarian Cancer, More Delimited Panel Composition Needed to Improve Utility

February 16th 2021

February 16, 2021 - Only 34.3% of 14,689 patients with ovarian cancer received germline genetic testing between 2013 and 2019, revealing persistent underuse of testing among this population.

Lack of Concordance Regarding Plasma Testing in Lung Cancer Must Be Overcome

February 16th 2021

Andrew Mckenzie, PhD, discusses the differences between tissue- and plasma-based NGS tests, factors that can lead to a lack of concordance, and important areas of ongoing research.

Targeted Therapies Reign in the Frontline Treatment of CLL

February 16th 2021

Jacqueline Claudia Barrientos, MD, MS, explaines how she navigates among the options available in the frontline setting for patients with CLL and highlighted ongoing research efforts of interest.

Epperla Elucidates on Excitement With Tafasitamab and Selinexor in DLBCL

February 15th 2021

Narendranath Epperla, MD, MS, expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and other options in the pipeline.

BCG Plus N-803 Elicits Positive Responses, Tolerability in BCG-Unresponsive NMIBC CIS

February 13th 2021

February 13, 2021 - Bacillus calmette-guérin plus N-803 demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer carcinoma in situ

Axi-Cel Active in Relapsed/Refractory B-Cell Lymphomas Irrespective of Chemo Sensitivity

February 9th 2021

February 9, 2021 - Responsiveness to treatment received immediately prior to CAR T-cell therapy may not be associated with post–CAR T outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma who receive axicabtagene ciloleucel.

Strategizing Effective Ways to Overcome TKI Resistance in ALK+ NSCLC

February 8th 2021

Vincent Lam, MD, describes frontline indications for this patient population, as well as strategies that can be utilized to overcome TKI resistance in later lines of therapy.

Heterogeneity in Risk of COVID-19–Related Death Identified Across Different Cancer Subtypes

February 6th 2021

February 5, 2021 - Significant heterogeneity was identified in risk of coronavirus disease 2019–related death in patients based on factors such as cancer subtype, age, sex, and in-patient proportion.

MSKCC Strategizes to Provide Safe Outpatient Cancer Care During the COVID-19 Crisis

February 5th 2021

February 4, 2021 - Despite the threat the coronavirus disease 2019 presents, it’s necessary that patients with cancer continue to receive care at outpatient facilities—a feat that has been made possible at Memorial Sloan Kettering Cancer Center through multidisciplinary efforts, innovative strategy, and technologic advances.